Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    N01379
Show Display Options
Rank Status Study
1 Active, not recruiting Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
Condition: Epilepsy
Intervention: Drug: Brivaracetam
2 Active, not recruiting Veliparib With or Without Carboplatin in Treating Patients With Stage III or Stage IV Breast Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years